Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07824206
PHASE4
Lumateperone Added to Antidepressant Therapy in Adults With Major Depressive Disorder Experiencing Emotional Blunting
Sponsor: Future Options Research, LLC
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate whether or not adding lumateparone to current antidepressant treatment in adults with major depressive disorder experiencing blunted emotion will reduce or eliminate the blunted emotion as rated by the Oxford Depression Questionnaire.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2026-09
Completion Date
2028-03
Last Updated
2026-09-17
Healthy Volunteers
No
Interventions
DRUG
lumateparone 42 mg once daily
lumateparone 42 mg once daily added to current antidepressant treatment
DRUG
lumateparone
Lumateparone
Locations (1)
Future Options Research
State College, Pennsylvania, United States